C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
|Articles|March 19, 2019
Quiz: Current Controversies Surrounding Lymphadenectomy in Prostate Cancer
In our March prostate cancer quiz, you'll get a chance to test your knowledge of current controversies surrounding the use of lymphadenectomy in prostate cancer.
Advertisement
In our March prostate cancer quiz, you'll get a chance to test your knowledge of current controversies surrounding the use of lymphadenectomy in prostate cancer. Here's your first question:
1. Pelvic lymph node dissection (PLND) has been definitively shown to improve which of the following among patients with prostate cancer?
A.Progression-free survival
B.Overall survival
C.Tumor staging
D.All of the above
Advertisement
Related to this article
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 PERSEUS study.
Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
5